A prospective, randomized, investigator-masked, crossover comparison;~Ocular hypertension or glaucoma (XFG or POAG) patients and who consent to participate will be enrolled in this study~Patients will be scheduled for a screening visit IOP assessment (IOP measurements at 08:30, 12:30 and 16:30 (±1 hour).~Patients who are on therapy at the screening visit and who consent to participate will undergo a washout period for 4 weeks (depending on therapy) before the baseline visit;~Patient can under the washout period be given brinzolamide (Azopt) if needed, Azopt should then be discontinued 5 days before baseline visit;~After the screening visit (and after wash-outperiod for treated patients) patients will be scheduled to undergo a baseline visit IOP assessment (IOP measurements at 08:30, 12:30 and 16:30 (± 1 hour with a minimum of 3 hours between readings) and will then be randomized for Period 1 to receive either BIMMD drops once in the evening (20:30) or TUDPF drops once in the evening (20:30) for 3 month~After 3 month, patients will be switched for Period 2, to the opposite treatment (e.g. switched to either BIMMD or TUDPF) to be dosed in the evening;~After another 3 months they will undergo the final evaluation of IOP levels and of tolerability;~Intermediate safety visits may be scheduled at the discretion of the investigator.
This cross-over study will investigate the efficacy and safety of BIMMD and TUDPF in a clinical setting.